The Providence Community Health Centers, Inc: drugs
Schedule G of this filing lists 172 drugs, with an amount and a number of claims for each, as filed. Every amount links to its page of the filing.
The schedule's total is printed as “Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement”. The filings describe the amounts in more than one way. Methods says more.
- 172drugs listed
- $8,143,697.89 (Schedule G, printed total, page 14 of the filing PDF)Total as filed
- 61,847 (Schedule G, printed claims total, page 14 of the filing PDF)Claims total as filed
- 28rows show “fewer than 6” for claims. What this means
All 172 drug rows
| Line | Drug | Amount as filed | Claims as filed |
|---|---|---|---|
| 1 | Biktarvy 50/200/25 mg tablets61958250101Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 648,404.79 (Schedule G, line 1, page 9 of the filing PDF) | 231 |
| 2 | Ozempic 0.25 or 0.5 mg DOS(2 mg/3 mL)00169418113Listed by the FDA as Ozempicsemaglutide0.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 636,465.60 (Schedule G, line 2, page 9 of the filing PDF) | 1,897 |
| 3 | Ozempic 1 mg per dose (4 mg/3 mL) PFP00169413013Listed by the FDA as Ozempicsemaglutide1.34 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 438,230.08 (Schedule G, line 3, page 9 of the filing PDF) | 1,239 |
| 4 | Ozempic 2 mg per dose (8 mg/3 mL) PFP00169477212Listed by the FDA as Ozempicsemaglutide2.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 360,640.64 (Schedule G, line 4, page 9 of the filing PDF) | 1,113 |
| 5 | Rinvoq 15 mg ER tablets00074230630Listed by the FDA as Rinvoqupadacitinib15 mgtablet, extended releaseAbbVie Inc. | 273,818.39 (Schedule G, line 5, page 9 of the filing PDF) | 89 |
| 6 | Xolair inj 150 mg/mL50242021503Listed by the FDA as Xolair PFSomalizumab150 mg/mLinjection, solutionGenentech, Inc. | 199,558.56 (Schedule G, line 6, page 9 of the filing PDF) | 96 |
| 7 | Skyrizi 150 mg/mL Singl dose pen 1 mL00074210001Listed by the FDA as Skyrizirisankizumab-rzaa150 mg/mLinjectionAbbVie Inc. | 193,859.16 (Schedule G, line 7, page 9 of the filing PDF) | 17 |
| 8 | Basaglar 100 units/mL KwikPen inj 3 mL00002771559Listed by the FDA as Basaglar KwikPeninsulin glargine100 IU/mLinjection, solutionEli Lilly and Company | 189,229.98 (Schedule G, line 8, page 9 of the filing PDF) | 349 |
| 9 | Tremfya inj 100 mg/mL57894064011Listed by the FDA as Tremfyaguselkumab100 mg/mLinjectionJanssen Biotech, Inc. | 171,290.76 (Schedule G, line 9, page 9 of the filing PDF) | 38 |
| 10 | Fasenra 30 mg/mL syr00310173030Listed by the FDA as Fasenrabenralizumab30 mg/mLinjection, solutionAstraZeneca Pharmaceuticals LP | 169,041.94 (Schedule G, line 10, page 9 of the filing PDF) | 44 |
| 11 | Trulicity 0.75 mg/0.5 mL inj (4 pens)00002143380Listed by the FDA as Trulicitydulaglutide0.75 mg/0.5 mLinjection, solutionEli Lilly and Company | 130,120.49 (Schedule G, line 11, page 9 of the filing PDF) | 295 |
| 12 | Rybelsus 14 mg tablets00169431430Listed by the FDA as Rybelsusoral semaglutide14 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 100,896.73 (Schedule G, line 12, page 9 of the filing PDF) | 204 |
| 13 | Dovato 50-300 mg tablets49702024613Listed by the FDA as Dovatodolutegravir sodium and lamivudine50 mg; 300 mgtablet, film coatedViiV Healthcare Company | 99,898.56 (Schedule G, line 13, page 9 of the filing PDF) | 45 |
| 14 | Erleada59676060012Listed by the FDA as Erleadaapalutamide60 mgtablet, film coatedJanssen Products, LP | 98,194.08 (Schedule G, line 14, page 9 of the filing PDF) | 10 |
| 15 | Xolair inj 150 mg/mL50242021501Listed by the FDA as Xolair PFSomalizumab150 mg/mLinjection, solutionGenentech, Inc.the product is listed, not this package | 97,035.38 (Schedule G, line 15, page 9 of the filing PDF) | 57 |
| 16 | Fasenra pen inj 30 mg/mL00310183030Listed by the FDA as Fasenrabenralizumab30 mg/mLinjection, solutionAstraZeneca Pharmaceuticals LP | 96,098.63 (Schedule G, line 16, page 9 of the filing PDF) | 24 |
| 17 | Wegovy 2.4 mg/0.75 mL inj (4 pens)00169452414Listed by the FDA as Wegovysemaglutide2.4 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 93,099.97 (Schedule G, line 17, page 9 of the filing PDF) | 157 |
| 18 | Paxlovid new 300/100 mg T standard00069532130Listed by the FDA as Paxlovidnirmatrelvir and ritonavirkitPfizer Laboratories Div Pfizer Inc | 91,793.24 (Schedule G, line 18, page 9 of the filing PDF) | 91 |
| 19 | Cosentyx Uno inj 300/2 mL00078107068Listed by the FDA as Cosentyxsecukinumab300 mg/2 mLinjectionNovartis Pharmaceuticals Corporation | 83,771.19 (Schedule G, line 19, page 9 of the filing PDF) | 32 |
| 20 | Skyrizi inj 150 mg/mL00074105001Listed by the FDA as Skyrizirisankizumab-rzaa150 mg/mLinjectionAbbVie Inc. | 79,833.55 (Schedule G, line 20, page 10 of the filing PDF) | 7 |
| 21 | Vosevi tablets61958240101Listed by the FDA as Vosevisofosbuvir, velpatasvir, and voxilaprevir400 mg; 100 mg; 100 mgtablet, film coatedGilead Sciences, Inc. | 75,305.94 (Schedule G, line 21, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 22 | Trelegy Ellipta 100-62.5 mcg inh 30P00173088710Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate100 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 73,000.87 (Schedule G, line 22, page 10 of the filing PDF) | 280 |
| 23 | Trulicity 1.5 mg/0.5 mL inj (4 pens)00002143480Listed by the FDA as Trulicitydulaglutide1.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 71,521.15 (Schedule G, line 23, page 10 of the filing PDF) | 180 |
| 24 | Trulicity 3 mg/0.5 mL inj (4 pens)00002223680Listed by the FDA as Trulicitydulaglutide3 mg/0.5 mLinjection, solutionEli Lilly and Company | 70,339.10 (Schedule G, line 24, page 10 of the filing PDF) | 85 |
| 25 | Mounjaro 5 mg/0.5 mL inj (4 pens)00002149580Listed by the FDA as Mounjarotirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 68,202.46 (Schedule G, line 25, page 10 of the filing PDF) | 73 |
| 26 | Wegovy 1.7 mg/0.75 mL inj ( 4 pens)00169451714Listed by the FDA as Wegovysemaglutide1.7 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 66,826.37 (Schedule G, line 26, page 10 of the filing PDF) | 113 |
| 27 | Descovy 200 mg/25 mg tablets61958200201Listed by the FDA as Descovyemtricitabine and tenofovir alafenamide200 mg; 25 mgtabletGilead Sciences, Inc. | 61,907.51 (Schedule G, line 27, page 10 of the filing PDF) | 56 |
| 28 | Rinvoq 45 mg ER tablets00074104328Listed by the FDA as Rinvoqupadacitinib45 mgtablet, extended releaseAbbVie Inc. | 59,641.01 (Schedule G, line 28, page 10 of the filing PDF) | 10 |
| 29 | Trelegy Ellipta 200-62.5 mcg inh 30P00173089310Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate200 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 58,560.58 (Schedule G, line 29, page 10 of the filing PDF) | 207 |
| 30 | Wegovy 1 mg/0.5 mL inj (4 pens)00169450114Listed by the FDA as Wegovysemaglutide1 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 57,281.63 (Schedule G, line 30, page 10 of the filing PDF) | 97 |
| 31 | Stelara 90 mg/mL PFS57894006103Listed by the FDA as Stelaraustekinumab90 mg/mLinjection, solutionJanssen Biotech, Inc. | 56,317.63 (Schedule G, line 31, page 10 of the filing PDF) | 7 |
| 32 | Rybelsus 7 mg tablets00169430730Listed by the FDA as Rybelsusoral semaglutide7 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 55,890.93 (Schedule G, line 32, page 10 of the filing PDF) | 127 |
| 33 | Wegovy 0.5 mg/0.5 mL inj (4 pens)00169450514Listed by the FDA as Wegovysemaglutide0.5 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 52,479.20 (Schedule G, line 33, page 10 of the filing PDF) | 89 |
| 34 | Mounjaro 7.5 mg/0.5 mL inj (4 pens)00002148480Listed by the FDA as Mounjarotirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 52,049.28 (Schedule G, line 34, page 10 of the filing PDF) | 54 |
| 35 | Nucala inj 100 mg/mL00173089242Listed by the FDA as Nucalamepolizumab100 mg/mLinjection, solutionGlaxoSmithKline LLC | 51,361.00 (Schedule G, line 35, page 10 of the filing PDF) | 20 |
| 36 | Dapagliflozin 5 mg tablets66993045630Listed by the FDA as Dapagliflozin5 mgtablet, film coatedPrasco Laboratories | 50,756.04 (Schedule G, line 36, page 10 of the filing PDF) | 209 |
| 37 | Nurtec 75 mg ODT tablets72618300002Listed by the FDA as Nurtec ODTrimegepant sulfate75 mgtablet, orally disintegratingPfizer Laboratories Div Pfizer Inc | 50,741.25 (Schedule G, line 37, page 10 of the filing PDF) | 95 |
| 38 | Mounjaro 2.5 mg/0.5 mL inj ( 4 pens)00002150680Listed by the FDA as Mounjarotirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 50,229.37 (Schedule G, line 38, page 10 of the filing PDF) | 64 |
| 39 | Mavyret tab 100-40 mg00074262528Listed by the FDA as Mavyretglecaprevir and pibrentasvir40 mg; 100 mgtablet, film coatedAbbVie Inc. | 48,447.48 (Schedule G, line 39, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 40 | Wegovy 0.25 mg/0.5 mL inj ( 4 pens)00169452514Listed by the FDA as Wegovysemaglutide0.25 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 48,025.94 (Schedule G, line 40, page 10 of the filing PDF) | 84 |
| 41 | Tremfya inj 100 mg/mL57894064001Listed by the FDA as Tremfyaguselkumab100 mg/mLinjectionJanssen Biotech, Inc. | 47,844.99 (Schedule G, line 41, page 10 of the filing PDF) | 11 |
| 42 | Trulicity 4.5 mg/0.5 mL inj (4 pens)00002318280Listed by the FDA as Trulicitydulaglutide4.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 46,814.14 (Schedule G, line 42, page 10 of the filing PDF) | 51 |
| 43 | Genvoya (150/150/200/TAF10) tab61958190101Listed by the FDA as Genvoyaelvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide150 mg; 150 mg; 200 mg; 10 mgtabletGilead Sciences, Inc. | 46,642.14 (Schedule G, line 43, page 10 of the filing PDF) | 19 |
| 44 | Humira pen 40 mg/0.4 mL kit(2pens)CF00074055402Listed by the FDA as HumiraadalimumabkitAbbVie Inc. | 46,414.82 (Schedule G, line 44, page 10 of the filing PDF) | 32 |
| 45 | Cosentyx pen inj 300dose00078063941Listed by the FDA as Cosentyxsecukinumab150 mg/mLinjectionNovartis Pharmaceuticals Corporation | 45,616.02 (Schedule G, line 45, page 10 of the filing PDF) | 29 |
| 46 | Entresto 24-26 mg tablets00078065920Listed by the FDA as Entrestosacubitril and valsartan24 mg; 26 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 43,830.73 (Schedule G, line 46, page 10 of the filing PDF) | 109 |
| 47 | Paxlovid standard dose 300/100 mg T00069504530Listed by the FDA as Paxlovidnirmatrelvir and ritonavirkitPfizer Laboratories Div Pfizer Inc | 43,213.60 (Schedule G, line 47, page 10 of the filing PDF) | 40 |
| 48 | Lonsurf64842102003Listed by the FDA as Lonsurftrifluridine and tipiracil20 mg; 8.19 mgtablet, film coatedTaiho Pharmaceutical Co., Ltd. | 43,091.00 (Schedule G, line 48, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 49 | Ilumya inj 100 mg/mL47335017795Listed by the FDA as Ilumyatildrakizumab-asmn100 mg/mLinjection, solutionSun Pharmaceutical Industries, Inc. | 37,651.12 (Schedule G, line 49, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 50 | Botox 200 units inj, 1 vial00023392102Listed by the FDA as BotoxonabotulinumtoxinA200 USP unitsinjection, powder, lyophilized, for solutionAllergan, Inc. | 35,529.88 (Schedule G, line 50, page 10 of the filing PDF) | 37 |
| 51 | Budesonide/FORM 160/4.5 mcg(120 inh)00310737020Listed by the FDA as Budesonide and Formoterol Fumarate Dihydrate160 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 35,400.09 (Schedule G, line 51, page 10 of the filing PDF) | 313 |
| 52 | Mounjaro 10 mg/0.5 mL inj (4 pens)00002147180Listed by the FDA as Mounjarotirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 35,319.54 (Schedule G, line 52, page 10 of the filing PDF) | 34 |
| 53 | Entresto 49-51 mg tablets00078077720Listed by the FDA as Entrestosacubitril and valsartan49 mg; 51 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 34,893.52 (Schedule G, line 53, page 10 of the filing PDF) | 80 |
| 54 | Botox 100 units injection00023114501Listed by the FDA as BotoxonabotulinumtoxinA100 USP unitsinjection, powder, lyophilized, for solutionAllergan, Inc. | 34,577.20 (Schedule G, line 54, page 10 of the filing PDF) | 46 |
| 55 | Budesonide/FORM 80/4.5 mcg (120 inh)00310737220Listed by the FDA as Budesonide and Formoterol Fumarate Dihydrate80 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 31,771.59 (Schedule G, line 55, page 10 of the filing PDF) | 335 |
| 56 | Erleada59676060430Listed by the FDA as Erleadaapalutamide240 mgtablet, film coatedJanssen Products, LP | 30,659.52 (Schedule G, line 56, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 57 | Prolia 60 mg/mL PF syr inj, 1 mL55513071021Listed by the FDA as Proliadenosumab60 mg/mLinjectionAmgen, Inc | 29,865.49 (Schedule G, line 57, page 10 of the filing PDF) | 36 |
| 58 | Juluca 50-25 mg tablets49702024213Listed by the FDA as Julucadolutegravir sodium and rilpivirine hydrochloride50 mg; 25 mgtablet, film coatedViiV Healthcare Company | 29,622.81 (Schedule G, line 58, page 11 of the filing PDF) | 12 |
| 59 | Zepbound 2.5 mg/0.5 mL inj (4PF pens)00002250680Listed by the FDA as Zepboundtirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 28,297.07 (Schedule G, line 59, page 11 of the filing PDF) | 34 |
| 60 | Gamunex-C inj 20 g/20013533080024Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 27,872.13 (Schedule G, line 60, page 11 of the filing PDF) | 11 |
| 61 | Ubrelvy 100 mg tablets00023650110Listed by the FDA as Ubrelvyubrogepant100 mgtabletAllergan, Inc. | 27,829.29 (Schedule G, line 61, page 11 of the filing PDF) | 65 |
| 62 | Xifaxan 550 mg tablets65649030302Listed by the FDA as Xifaxanrifaximin550 mgtabletSalix Pharmaceuticals, Inc. | 27,408.96 (Schedule G, line 62, page 11 of the filing PDF) | 20 |
| 63 | Qulipta 60 mg tablets00074709430Listed by the FDA as Quliptaatogepant60 mgtabletAbbVie Inc. | 27,134.13 (Schedule G, line 63, page 11 of the filing PDF) | 66 |
| 64 | Lynparza00310067912Listed by the FDA as Lynparzaolaparib150 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 25,922.10 (Schedule G, line 64, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 65 | Xolair inj 300/2 mL50242022701Listed by the FDA as Xolairomalizumab300 mg/2 mLinjection, solutionGenentech, Inc. | 25,553.59 (Schedule G, line 65, page 11 of the filing PDF) | 10 |
| 66 | Austedo XR tab 12 mg68546047156Listed by the FDA as Austedo XRdeutetrabenazine12 mgtablet, film coated, extended releaseTeva Neuroscience, Inc. | 25,233.77 (Schedule G, line 66, page 11 of the filing PDF) | 8 |
| 67 | Rybelsus 3 mg tablets00169430330Listed by the FDA as Rybelsusoral semaglutide3 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 24,446.31 (Schedule G, line 67, page 11 of the filing PDF) | 69 |
| 68 | Epinephrine 0.3 mg inj 2 pack00115169449Listed by the FDA as Epinephrine0.3 mg/0.3 mLinjectionAmneal Pharmaceuticals of New York LLC | 24,306.82 (Schedule G, line 68, page 11 of the filing PDF) | 269 |
| 69 | Dapagliflozin 10 mg tablets66993045730Listed by the FDA as Dapagliflozin10 mgtablet, film coatedPrasco Laboratories | 23,976.53 (Schedule G, line 69, page 11 of the filing PDF) | 97 |
| 70 | Entresto 97-103 mg tablets00078069620Listed by the FDA as Entrestosacubitril and valsartan97 mg; 103 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 23,885.04 (Schedule G, line 70, page 11 of the filing PDF) | 45 |
| 71 | Fluticasone HFA 44 mcg inh 120inh66993007896Listed by the FDA as Fluticasone Propionate HFA44 mcgaerosol, meteredPrasco Laboratories | 23,310.73 (Schedule G, line 71, page 11 of the filing PDF) | 336 |
| 72 | Ingrezza cap 80 mg70370108001Listed by the FDA as Ingrezzavalbenazine80 mgcapsuleNeurocrine Biosciences, Inc. | 23,263.68 (Schedule G, line 72, page 11 of the filing PDF) | 6 |
| 73 | Tivicay 50 mg tablets49702022813Listed by the FDA as Tivicaydolutegravir sodium50 mgtablet, film coatedViiV Healthcare Company | 22,604.87 (Schedule G, line 73, page 11 of the filing PDF) | 22 |
| 74 | Mounjaro 12.5 mg/0.5 mL inj (4 pens)00002146080Listed by the FDA as Mounjarotirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 22,313.80 (Schedule G, line 74, page 11 of the filing PDF) | 22 |
| 75 | Mekinist tab 0.5 mg00078110515Listed by the FDA as Mekinisttrametinib0.5 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 20,888.47 (Schedule G, line 75, page 11 of the filing PDF) | 9 |
| 76 | Fluticasone HFA 110 mcg oral inh66993007996Listed by the FDA as Fluticasone Propionate HFA110 mcgaerosol, meteredPrasco Laboratories | 20,289.61 (Schedule G, line 76, page 11 of the filing PDF) | 221 |
| 77 | Odefsey (FTC200/RPV25/TAF25) tab61958210101Listed by the FDA as Odefseyemtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide200 mg; 25 mg; 25 mgtabletGilead Sciences, Inc. | 20,115.66 (Schedule G, line 77, page 11 of the filing PDF) | 9 |
| 78 | Zoryve 0.3% topical foam 60 g80610043060Listed by the FDA as Zoryveroflumilast3 mg/gaerosol, foamArcutis Biotherapeutics, Inc. | 19,220.86 (Schedule G, line 78, page 11 of the filing PDF) | 32 |
| 79 | Belbuca 900 mcg buccal film59385002760Listed by the FDA as Belbucabuprenorphine hydrochloride900 mcgfilm, solubleBioDelivery Sciences International Inc | 19,152.53 (Schedule G, line 79, page 11 of the filing PDF) | 61 |
| 80 | Zarxio61314032610Listed by the FDA as Zarxiofilgrastim-sndz480 mcg/0.8 mLinjection, solutionSandoz Inc. | 19,146.75 (Schedule G, line 80, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 81 | Bimzelx inj 320 mg/250474078284Listed by the FDA as Bimzelxbimekizumab320 mg/2 mLinjection, solutionUCB, Inc. | 18,443.61 (Schedule G, line 81, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 82 | Zepbound 5 mg/0.5 mL inj (4 PF pens)00002249580Listed by the FDA as Zepboundtirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 18,269.34 (Schedule G, line 82, page 11 of the filing PDF) | 22 |
| 83 | Actemra inj 162/0.950242013801Listed by the FDA as Actemratocilizumab162 mg/0.9 mLinjection, solutionGenentech, Inc. | 18,030.88 (Schedule G, line 83, page 11 of the filing PDF) | 8 |
| 84 | Invokana 100 mg tablets50458014030Listed by the FDA as Invokanacanagliflozin100 mgtablet, film coatedJanssen Pharmaceuticals, Inc. | 18,028.20 (Schedule G, line 84, page 11 of the filing PDF) | 77 |
| 85 | Benlysta inj 200 mg/mL49401008847Listed by the FDA as Benlystabelimumab200 mg/mLsolutionGlaxoSmithKline LLC | 17,787.65 (Schedule G, line 85, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 86 | Vemlidy 25 mg tablets61958230101Listed by the FDA as Vemlidytenofovir alafenamide25 mgtabletGilead Sciences, Inc. | 17,058.69 (Schedule G, line 86, page 11 of the filing PDF) | 13 |
| 87 | Breo Ellipta 100-25 mcg oral inh(30)00173085910Listed by the FDA as Breo Elliptafluticasone furoate and vilanterol trifenatate100 mcg; 25 mcgpowderGlaxoSmithKline LLC | 16,539.79 (Schedule G, line 87, page 11 of the filing PDF) | 171 |
| 88 | Stelara inj 45/0.5 mL57894006003Listed by the FDA as Stelaraustekinumab45 mg/0.5 mLinjection, solutionJanssen Biotech, Inc. | 16,501.80 (Schedule G, line 88, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 89 | Prevymis tab 480 mg00006307602Listed by the FDA as Prevymisletermovir480 mgtablet, film coatedMerck Sharp & Dohme LLC | 15,706.12 (Schedule G, line 89, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 90 | Jardiance 10 mg tablets00597015230Listed by the FDA as Jardianceempagliflozin10 mgtablet, film coatedBoehringer Ingelheim Pharmaceuticals, Inc. | 15,393.41 (Schedule G, line 90, page 11 of the filing PDF) | 743 |
| 91 | Hizentra inj 10/50 mL44206045525Listed by the FDA as Hizentrahuman immunoglobulin G0.2 g/mLliquidCSL Behring AG | 15,175.52 (Schedule G, line 91, page 11 of the filing PDF) | 7 |
| 92 | Caplyta cap 42 mg72060014240Listed by the FDA as Caplytalumateperone42 mgcapsuleIntra-Cellular Therapies, Inc | 15,110.86 (Schedule G, line 92, page 11 of the filing PDF) | 10 |
| 93 | Zafemy Patches65162035803Listed by the FDA as Zafemynorelgestromin and ethinyl estradiol150 mcg/day; 35 mcg/daypatchAmneal Pharmaceuticals LLC | 14,520.29 (Schedule G, line 93, page 11 of the filing PDF) | 146 |
| 94 | Zepbound 10 mg/0.5 mL inj (4 PF pens)00002247180Listed by the FDA as Zepboundtirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 14,154.21 (Schedule G, line 94, page 11 of the filing PDF) | 17 |
| 95 | Jardiance 25 mg tablets00597015330Listed by the FDA as Jardianceempagliflozin25 mgtablet, film coatedBoehringer Ingelheim Pharmaceuticals, Inc. | 14,140.92 (Schedule G, line 95, page 11 of the filing PDF) | 912 |
| 96 | Vraylar 3 mg capsules61874013030Listed by the FDA as Vraylarcariprazine3 mgcapsule, gelatin coatedAllergan, Inc. | 14,097.02 (Schedule G, line 96, page 12 of the filing PDF) | 17 |
| 97 | Wixela Inhub Diskus 250/50 mcg 60S00378932132Listed by the FDA as Wixela Inhubfluticasone propionate and salmeterol250 mcg; 50 mcgpowderMylan Pharmaceuticals Inc. | 13,605.51 (Schedule G, line 97, page 12 of the filing PDF) | 292 |
| 98 | Vascepa cap 1 g52937000120Listed by the FDA as Vascepaicosapent ethyl1,000 mgcapsuleAmarin Pharma Inc. | 13,445.92 (Schedule G, line 98, page 12 of the filing PDF) | 25 |
| 99 | Steglatro 15 mg tablets00006536403Listed by the FDA as Steglatroertugliflozin15 mgtablet, film coatedMerck Sharp & Dohme LLC | 13,151.21 (Schedule G, line 99, page 12 of the filing PDF) | 54 |
| 100 | Insulin Glarg-yfgn 100 units/mL pen inj83257001532Listed by the FDA as Insulin Glargineinsulin glargine-yfgn100 IU/mLinjection, solutionBiocon Biologics Inc. | 12,909.52 (Schedule G, line 100, page 12 of the filing PDF) | 346 |
| 101 | Ubrelvy 50 mg tablets00023649810Listed by the FDA as Ubrelvyubrogepant50 mgtabletAllergan, Inc. | 12,857.37 (Schedule G, line 101, page 12 of the filing PDF) | 25 |
| 102 | Januvia 100 mg tablets00006027731Listed by the FDA as Januviasitagliptin100 mgtablet, film coatedMerck Sharp & Dohme LLC | 12,608.00 (Schedule G, line 102, page 12 of the filing PDF) | 204 |
| 103 | Apretude 600 mg/3 mL ER inj susp, 3 mL49702026423Listed by the FDA as ApretudecabotegravirkitViiV Healthcare Company | 12,553.06 (Schedule G, line 103, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 104 | Mounjaro 15 mg/0.5 mL inj ( 4 pens)00002145780Listed by the FDA as Mounjarotirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 12,231.78 (Schedule G, line 104, page 12 of the filing PDF) | 13 |
| 105 | Qvar Redihaler 80 mcg Oralinh (120)59310030480Listed by the FDA as Qvar Redihalerbeclomethasone dipropionate HFA80 mcgaerosol, meteredTeva Respiratory, LLC | 11,958.64 (Schedule G, line 105, page 12 of the filing PDF) | 159 |
| 106 | Qvar Redihaler 40 mcg Oralinh (120)59310030240Listed by the FDA as Qvar Redihalerbeclomethasone dipropionate HFA40 mcgaerosol, meteredTeva Respiratory, LLC | 11,867.75 (Schedule G, line 106, page 12 of the filing PDF) | 186 |
| 107 | Albuterol HFA inh (200 puffs) 18 g66993001968Listed by the FDA as Albuterol Sulfate HFA90 mcgaerosol, meteredPrasco Laboratories | 11,859.45 (Schedule G, line 107, page 12 of the filing PDF) | 528 |
| 108 | Incruse Ellipta 62.5 mcg oral inh 3000173087310Listed by the FDA as Incruse Elliptaumeclidinium62.5 mcgaerosol, powderGlaxoSmithKline LLC | 11,829.40 (Schedule G, line 108, page 12 of the filing PDF) | 138 |
| 109 | Xolair inj 300/2 mL50242022755Listed by the FDA as Xolairomalizumab300 mg/2 mLinjection, solutionGenentech, Inc. | 11,657.98 (Schedule G, line 109, page 12 of the filing PDF) | 6 |
| 110 | Tysabri inj 300/15 mL64406000801Listed by the FDA as Tysabrinatalizumab300 mg/15 mLinjectionBiogen Inc. | 11,226.05 (Schedule G, line 110, page 12 of the filing PDF) | 8 |
| 111 | Gemtesa 75 mg tablets73336007530Listed by the FDA as Gemtesavibegron75 mgtablet, film coatedSumitomo Pharma America, Inc. | 11,093.91 (Schedule G, line 111, page 12 of the filing PDF) | 46 |
| 112 | Kerendia tab 10 mg50419054001Listed by the FDA as Kerendiafinerenone10 mgtablet, film coatedBayer HealthCare Pharmaceuticals Inc. | 10,880.79 (Schedule G, line 112, page 12 of the filing PDF) | 21 |
| 113 | Yeztugo 463.5 mg/1.5 mL inj, 2x1.5 mL61958340201Listed by the FDA as Yeztugolenacapavir sodiumkitGilead Sciences, Inc. | 10,849.82 (Schedule G, line 113, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 114 | Xolair inj 150 mg/mL50242021555Listed by the FDA as Xolair PFSomalizumab150 mg/mLinjection, solutionGenentech, Inc. | 10,664.08 (Schedule G, line 114, page 12 of the filing PDF) | 7 |
| 115 | Simlandi 2PN 40/0.4 mL auto-inj kit51759040202Listed by the FDA as Simlandiadalimumab-ryvkkitTeva Pharmaceuticals USA, Inc. | 10,649.08 (Schedule G, line 115, page 12 of the filing PDF) | 20 |
| 116 | Copaxone inj 40 mg/mL68546032512Listed by the FDA as Copaxoneglatiramer acetate40 mg/mLinjection, solutionTeva Neuroscience, Inc. | 10,571.79 (Schedule G, line 116, page 12 of the filing PDF) | 8 |
| 117 | Invega Sustenna 234 mg/1.5 mL inj50458056401Listed by the FDA as Invega Sustennapaliperidone palmitate234 mg/1.5 mLinjectionJanssen Pharmaceuticals, Inc. | 10,524.93 (Schedule G, line 117, page 12 of the filing PDF) | 9 |
| 118 | Epclusa tab 400-10061958220101Listed by the FDA as Epclusavelpatasvir and sofosbuvir100 mg; 400 mgtablet, film coatedGilead Sciences, Inc. | 10,483.20 (Schedule G, line 118, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 119 | Combivent Respimat oral 120spray 4 g00597002402Listed by the FDA as Combivent Respimatipratropium bromide and albuterol20 mcg; 100 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 10,251.04 (Schedule G, line 119, page 12 of the filing PDF) | 46 |
| 120 | Alogliptin 25 mg tablets45802015065Listed by the FDA as Alogliptin25 mgtablet, film coatedPadagis Israel Pharmaceuticals Ltd | 10,122.89 (Schedule G, line 120, page 12 of the filing PDF) | 126 |
| 121 | Cetirizine 1 mg/mL oral solution00121087416Listed by the FDA as Cetirizine Hydrochloride1 mg/mLsolutionPAI Holdings, LLC dba PAI Pharma | 10,116.96 (Schedule G, line 121, page 12 of the filing PDF) | 566 |
| 122 | Hadlima push inj 40/0.4 mL78206018701Listed by the FDA as Hadlimaadalimumab-bwwd40 mg/0.4 mLsolutionOrganon LLC | 10,097.92 (Schedule G, line 122, page 12 of the filing PDF) | 13 |
| 123 | Zepbound 7.5 mg/0.5 mL inj(4PF pens)00002248480Listed by the FDA as Zepboundtirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 9,970.39 (Schedule G, line 123, page 12 of the filing PDF) | 12 |
| 124 | Emgality 120 mg/mL auto injector 1 mL00002143611Listed by the FDA as Emgalitygalcanezumab-gnlm120 mg/mLinjection, solutionEli Lilly and Company | 9,926.88 (Schedule G, line 124, page 12 of the filing PDF) | 18 |
| 125 | Cosentyx pen inj 150 mg/mL00078063968Listed by the FDA as Cosentyxsecukinumab150 mg/mLinjectionNovartis Pharmaceuticals Corporation | 9,920.99 (Schedule G, line 125, page 12 of the filing PDF) | 15 |
| 126 | Taltz 80 mg/mL pen (1=1)00002144511Listed by the FDA as Taltzixekizumab80 mg/mLinjection, solutionEli Lilly and Company | 9,868.29 (Schedule G, line 126, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 127 | Xulane Patches00378334053Listed by the FDA as Xulanenorelgestromin and ethinyl estradiol150 mcg/day; 35 mcg/daypatchMylan Pharmaceuticals Inc. | 9,865.58 (Schedule G, line 127, page 12 of the filing PDF) | 65 |
| 128 | Vraylar 1.5 mg capsules61874011530Listed by the FDA as Vraylarcariprazine1.5 mgcapsule, gelatin coatedAllergan, Inc. | 9,750.38 (Schedule G, line 128, page 12 of the filing PDF) | 12 |
| 129 | Austedo XR tab 24 mg68546047256Listed by the FDA as Austedo XRdeutetrabenazine24 mgtablet, film coated, extended releaseTeva Neuroscience, Inc. | 9,576.76 (Schedule G, line 129, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 130 | Adbry inj 300/2 mL50222035002Listed by the FDA as Adbrytralokinumab-ldrm300 mg/2 mLinjection, solutionLEO Pharma Inc. | 9,536.06 (Schedule G, line 130, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 131 | Rinvoq tab 30 mg ER00074231030Listed by the FDA as Rinvoqupadacitinib30 mgtablet, extended releaseAbbVie Inc. | 9,443.86 (Schedule G, line 131, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 132 | Valtoco 10 mg nasal spr (5x10 mg spr)72252051005Listed by the FDA as Valtocodiazepam10 mg/0.1 mLsprayNeurelis, Inc | 8,796.38 (Schedule G, line 132, page 12 of the filing PDF) | 7 |
| 133 | Tresiba Flextouch pen (U-100)inj3 mL00169266015Listed by the FDA as Tresibainsulin degludec100 units/mLinjection, solutionNovo Nordisk | 8,707.60 (Schedule G, line 133, page 12 of the filing PDF) | 90 |
| 134 | Opzelura 1.5% cream 60 g50881000705Listed by the FDA as Opzeluraruxolitinib15 mg/gcreamIncyte Corporation | 8,645.85 (Schedule G, line 134, page 13 of the filing PDF) | 7 |
| 135 | Qulipta 30 mg tablets00074709630Listed by the FDA as Quliptaatogepant30 mgtabletAbbVie Inc. | 8,296.32 (Schedule G, line 135, page 13 of the filing PDF) | 20 |
| 136 | Enbrel 50 mg/mL inj (4 Syringes)58406002104Listed by the FDA as Enbreletanercept50 mg/mLsolutionImmunex Corporation | 8,058.12 (Schedule G, line 136, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 137 | Slynd 4 mg tablets 28S00642747001Listed by the FDA as SlynddrospirenonekitExeltis USA, Inc. | 7,863.24 (Schedule G, line 137, page 13 of the filing PDF) | 44 |
| 138 | Steglatro 5 mg tablets00006536303Listed by the FDA as Steglatroertugliflozin5 mgtablet, film coatedMerck Sharp & Dohme LLC | 7,778.05 (Schedule G, line 138, page 13 of the filing PDF) | 29 |
| 139 | Wixela Inhub Diskus 500/50 mcg 60S00378932232Listed by the FDA as Wixela Inhubfluticasone propionate and salmeterol500 mcg; 50 mcgpowderMylan Pharmaceuticals Inc. | 7,707.16 (Schedule G, line 139, page 13 of the filing PDF) | 99 |
| 140 | Nucala inj 100 mg/mL00173089201Listed by the FDA as Nucalamepolizumab100 mg/mLinjection, solutionGlaxoSmithKline LLC | 7,704.15 (Schedule G, line 140, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 141 | Flutic/Vilan 200-25 mcg oral inh(30)66993013697Listed by the FDA as Fluticasone Furoate and Vilanterol200 mcg; 25 mcgpowderPrasco Laboratories | 7,476.71 (Schedule G, line 141, page 13 of the filing PDF) | 44 |
| 142 | Flutic/Vilan 100-25 mcg oral inh(30)66993013597Listed by the FDA as Fluticasone Furoate and Vilanterol100 mcg; 25 mcgpowderPrasco Laboratories | 7,444.90 (Schedule G, line 142, page 13 of the filing PDF) | 50 |
| 143 | Ajovy 225 mg/1.5 mL PF AUT inj 1.5 mL51759020210Listed by the FDA as Ajovyfremanezumab-vfrm225 mg/1.5 mLinjectionTeva Pharmaceuticals USA, Inc. | 7,423.58 (Schedule G, line 143, page 13 of the filing PDF) | 37 |
| 144 | Dupixent 300 mg/2 mL PF pen 2x2 mL00024591502Listed by the FDA as Dupixentdupilumab300 mg/2 mLinjection, solutionSanofi-Aventis U.S. LLC | 7,395.69 (Schedule G, line 144, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 145 | Vivitrol 380 mg inj, 1 vial65757030001Listed by the FDA as VivitrolnaltrexonekitAlkermes, Inc. | 7,247.44 (Schedule G, line 145, page 13 of the filing PDF) | 10 |
| 146 | Orencia 125 mg/mL PF syr 4x1 mL00003218811Listed by the FDA as Orenciaabatacept125 mg/mLinjection, solutionE.R. Squibb & Sons, L.L.C. | 7,226.35 (Schedule G, line 146, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 147 | Mirabegron 25 mg ER tablets68180015106Listed by the FDA as Mirabegron25 mgtablet, film coated, extended releaseLupin Pharmaceuticals, Inc. | 7,203.36 (Schedule G, line 147, page 13 of the filing PDF) | 37 |
| 148 | Spiriva Respimat 2.5 mcg inh 4 g 60D00597010061Listed by the FDA as Spiriva Respimattiotropium bromide inhalation spray3.124 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 7,090.69 (Schedule G, line 148, page 13 of the filing PDF) | 81 |
| 149 | Xcopri 200 mg tablets71699020030Listed by the FDA as Xcopricenobamate200 mgtablet, film coatedSK Life Science, Inc. | 7,039.02 (Schedule G, line 149, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 150 | Hadlima inj 40/0.4 mL78206018601Listed by the FDA as Hadlimaadalimumab-bwwd40 mg/0.4 mLsolutionOrganon LLC | 6,942.32 (Schedule G, line 150, page 13 of the filing PDF) | 11 |
| 151 | Xolair inj 75/0.550242021403Listed by the FDA as Xolair PFSomalizumab75 mg/0.5 mLinjection, solutionGenentech, Inc. | 6,941.56 (Schedule G, line 151, page 13 of the filing PDF) | 8 |
| 152 | Vraylar cap 4.5 mg61874014530Listed by the FDA as Vraylarcariprazine4.5 mgcapsule, gelatin coatedAllergan, Inc. | 6,874.98 (Schedule G, line 152, page 13 of the filing PDF) | 8 |
| 153 | Lantus Solostar pen inj 3 mL00088221905Listed by the FDA as Lantus Solostarinsulin glargine100 IU/mLinjection, solutionsanofi-aventis U.S. LLC | 6,728.10 (Schedule G, line 153, page 13 of the filing PDF) | 470 |
| 154 | Invokana 300 mg tablets50458014130Listed by the FDA as Invokanacanagliflozin300 mgtablet, film coatedJanssen Pharmaceuticals, Inc. | 6,436.07 (Schedule G, line 154, page 13 of the filing PDF) | 32 |
| 155 | Ajovy 225 mg/1.5 mL PF syr 1.5 mL51759020410Listed by the FDA as Ajovyfremanezumab-vfrm225 mg/1.5 mLinjectionTeva Pharmaceuticals USA, Inc. | 6,430.35 (Schedule G, line 155, page 13 of the filing PDF) | 32 |
| 156 | Novolog Flexpen inj 3 mL (Orange)00169633910Listed by the FDA as Novologinsulin aspart100 IU/mLinjection, solutionNovo Nordisk | 6,264.55 (Schedule G, line 156, page 13 of the filing PDF) | 80 |
| 157 | Steqeyma 90 mg/mL syr 1=172606002801Listed by the FDA as Steqeymaustekinumab-stba90 mg/mLinjection, solutionCELLTRION USA, Inc. | 6,192.63 (Schedule G, line 157, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 158 | Arnuity Ellipta 100 mcg oral inh 3000173087410Listed by the FDA as Arnuity Elliptafluticasone furoate100 mcgpowderGlaxoSmithKline LLC | 6,140.89 (Schedule G, line 158, page 13 of the filing PDF) | 125 |
| 159 | Austedo tab 6 mg68546017060Listed by the FDA as Austedodeutetrabenazine6 mgtablet, coatedTeva Neuroscience, Inc. | 6,101.95 (Schedule G, line 159, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 160 | Lokelma 10 g Packets00310111030Listed by the FDA as Lokelmasodium zirconium cyclosilicate10 g/10 gpowder, for suspensionAstraZeneca Pharmaceuticals LP | 6,046.92 (Schedule G, line 160, page 13 of the filing PDF) | 14 |
| 161 | Wixela Inhub Diskus 100/50 mcg 60S00378932032Listed by the FDA as Wixela Inhubfluticasone propionate and salmeterol100 mcg; 50 mcgpowderMylan Pharmaceuticals Inc. | 6,035.91 (Schedule G, line 161, page 13 of the filing PDF) | 185 |
| 162 | Fluticasone HFA 220 mcg oral inh66993008096Listed by the FDA as Fluticasone Propionate HFA220 mcgaerosol, meteredPrasco Laboratories | 5,920.76 (Schedule G, line 162, page 13 of the filing PDF) | 42 |
| 163 | Liraglutide 18 mg/3 mL inj pen (3PK)00480366722Listed by the FDA as Liraglutide6 mg/mLinjectionTeva Pharmaceuticals USA, Inc. | 5,900.80 (Schedule G, line 163, page 13 of the filing PDF) | 27 |
| 164 | Breyna 80/4.5 mcg oral inh (120 inh)00378750232Listed by the FDA as Breynabudesonide and formoterol fumarate80 mcg; 4.5 mcgaerosol, meteredMylan Pharmaceuticals Inc. | 5,802.39 (Schedule G, line 164, page 13 of the filing PDF) | 46 |
| 165 | Eliquis 5 mg tablets00003089421Listed by the FDA as Eliquisapixaban5 mgtablet, film coatedE.R. Squibb & Sons, L.L.C. | 5,757.25 (Schedule G, line 165, page 13 of the filing PDF) | 216 |
| 166 | Tradjenta 5 mg tablets00597014030Listed by the FDA as Tradjentalinagliptin5 mgtablet, film coatedBoehringer Ingelheim Pharmaceuticals, Inc. | 5,562.13 (Schedule G, line 166, page 13 of the filing PDF) | 171 |
| 167 | Biktarvy tab61958250103Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 5,562.12 (Schedule G, line 167, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 168 | Ventolin HFA inh W/DOS CTR 200puffs00173068220Listed by the FDA as Ventolin HFAalbuterol sulfate90 mcgaerosol, meteredGlaxoSmithKline LLC | 5,284.57 (Schedule G, line 168, page 13 of the filing PDF) | 321 |
| 169 | Otezla 28 day Starter pack55513036955Listed by the FDA as OtezlaapremilastkitAmgen, Inc | 5,259.32 (Schedule G, line 169, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 170 | Zoryve 0.15% cream 60 g80610011560Listed by the FDA as Zoryveroflumilast1.5 mg/gcreamArcutis Biotherapeutics, Inc. | 5,258.79 (Schedule G, line 170, page 13 of the filing PDF) | 9 |
| 171 | Levalbuterol HFA inh (200PF) 15 g00591292754Listed by the FDA as Levalbuterol tartrate HFA inhalationlevalbuterol tartrate45 mcgaerosol, meteredActavis Pharma, Inc. | 5,158.93 (Schedule G, line 171, page 13 of the filing PDF) | 175 |
| 172 | Valtoco 15 mg NAS SP(10x7.5 mg)5 dose72252051510Listed by the FDA as Valtocodiazepam7.5 mg/0.1 mLsprayNeurelis, Inc | 5,038.15 (Schedule G, line 172, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
No row matches. | |||
| Total Prescription Drugs individually under $5,000 | 568,968.95 (Schedule G, row for amounts under $5,000, page 14 of the filing PDF) | 43,637 (Schedule G, claims on the row for amounts under $5,000, page 14 of the filing PDF) | |
| Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement | 8,143,697.89 (Schedule G, printed total, page 14 of the filing PDF) | 61,847 (Schedule G, printed claims total, page 14 of the filing PDF) | |
The rows at the foot of the table are always shown. The sum above does not include them.
What “fewer than 6” means. A count of 1 to 5 is not shown on this site or in its data files. Methods, section 9, says how.
Amounts and counts are the filer’s own, in US dollars. They are written here with commas between thousands, and an amount filed with one decimal place is written with two. No value is changed: the filing and the download keep each figure as typed.
Drug names are the filer’s own words. Filers type them in many ways, so this page writes them one way: capitals, spaces, unit names such as mg and mL, a zero before a decimal point, and commas in long numbers. No word is changed, spelled out or left out, and shorthand stays as the filer typed it. The filing and the download keep each name as typed, and a search here reads both.
“Listed by the FDA as” is not part of the filing. It is the name, ingredient, strength, form and labeler that the U.S. Food and Drug Administration’s National Drug Code Directory lists for the row’s code, as downloaded on 11 November 2026. All 172 rows have one. A row has none when its code is not filed as one 11-digit code or the directory has never listed it. Where the directory has since dropped a code, the name is kept as it was last listed, and the line says so. The directory’s capitals, strengths and unit names are written one way on this page. How a code is matched
Source
- Filing PDF
- Open Schedule G on the State of Rhode Island's website
- SHA-256
- fb7ac35095fe2e677e8569bf5a2d6f6c213006b8c6b004b012083af7608d67ea
- Retrieved
- 11 November 2026
- Pages used
- 9 to 14 of 16